65 A Retrospective Cohort Study of the Use of Vivostat PRF Autologous Platelet-Rich Fibrin in Patient Outcomes in Total Knee Replacement Surgery

Aim Vivostat PRF is an autologous platelet-rich fibrin spray that is prepared in theatre from the patient’s own blood and has shown that its use as a biological sealant intra-operatively reduces transfusion rates and decreases haemarthrosis after total knee replacement (TKR). We undertook a retrospective time-based comparative cohort study examining relevant patient outcomes, comparing patients undergoing TKR surgery with Vivostat PRF versus without. Method 106 patients undergoing TKR surgery between 2008 and 2017 were studied. Patients were selected for inclusion via hospital records and divided into two groups: those who had received Vivostat PRF intra-operatively (n = 59), and those who hadn’t (n = 47) (the control group). Primary outcomes included haemoglobin drop pre- vs post-operatively, range of movement (ROM) at follow-up appointments, number of days post-operatively in hospital until the patient was able to manage stairs, post-operative pain scores and transfusion rates. Results There was a statistically significant difference in the haemoglobin drop between the two groups, with a drop of 27.5g/L in the study group compared to 31.9g/L in the control group (p = 0.019). ROM at day 3 post-operatively was better in the Vivostat group by 5.0o (p = 0.0018), and at 3 months post-operatively there was 7.8o greater movement (p = 0.004). No statistically significant differences were seen in the pain scores; however, early rehabilitation performance was improved in the Vivostat group, with a quicker time to being able to manage stairs post-operatively (p = 0.04). There was no statistically significant difference in transfusion rates. Conclusions This study showed that there are benefits in using Vivostat PRF in TKR surgery.